12 Drugs Approved for Primary Care in 2021

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

News

Slideshow

With 2021 nearing an end, Patient Care Online has compiled a list of key drugs approved this year by the US Food and Drug Administration for conditions that are often seen in primary care. Scroll through the slides below to find details on the novel COVID-19 vaccine, a novel agent for the treatment of heart failure, the first and only antihistamine nasal spray for allergies available over-the-counter, and 9 more.

Related Content

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

August 30th 2023

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Patient Care Staff

Obesity & Type 2 Diabetes: An Expert Discussion

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

June 30th 2023

FDA Proposed Rule Would Limit Nicotine Content in Cigarettes, Cigars, Other Combusted Products

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

FDA Limit Nicotine Content in Cigarettes, Cigars, Other Products / image credit ©Solid Photos/stock.adobe.com

Richard Payerchin

CAH Update: High-Level Examination of Condition Published in Expert Review of Endocrinology & Metabolism, Neurocrine Announces

The agency estimates that limiting nicotine levels could lead to 1.8 million fewer tobacco-related deaths by 2060 and health care savings of $1.1 trillion a year over the next 40 years.

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

"Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms," offers an in-depth look at the disorder and promising therapies.

Related Content

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

August 30th 2023

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Patient Care Staff

Obesity & Type 2 Diabetes: An Expert Discussion

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

June 30th 2023

FDA Proposed Rule Would Limit Nicotine Content in Cigarettes, Cigars, Other Combusted Products

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Richard Payerchin

CAH Update: High-Level Examination of Condition Published in Expert Review of Endocrinology & Metabolism, Neurocrine Announces

The agency estimates that limiting nicotine levels could lead to 1.8 million fewer tobacco-related deaths by 2060 and health care savings of $1.1 trillion a year over the next 40 years.